stockrow
Friday 6 November 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
67.74
0.22
+0.33%
Follow TARS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.35 | 4.50 | 5.63 | 7.58 | |
P/FCF ratio |
155.67 | 58.11 | 0.00 | 0.00 | |
P/Operating CF |
(607.99) | 44.61 | (122.24) | 176.99 | |
P/B ratio |
35.08 | 7.88 | 8.64 | 9.96 | |
Price to Tangible BV |
41.76 | 8.04 | 8.82 | 10.18 | |
EV/Sales |
5.00 | 3.88 | 5.04 | 6.81 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
68.39 | 31.75 | (163.95) | (247.04) | |
EV/FCF |
145.58 | 50.09 | (66.54) | (98.24) | |
Quick Ratio |
1.81 | 3.12 | 3.53 | 3.72 | |
Current Ratio |
1.96 | 3.20 | 3.74 | 3.85 | |
Net Debt/EBITDA |
0.36 | 19.33 | 49.59 | 41.60 | |
Debt/Assets |
14.43% | 11.91% | 12.49% | 12.89% | |
Debt/Equity |
0.70 | 0.21 | 0.21 | 0.21 | |
Asset Turnover |
1.31 | 1.10 | 0.99 | 0.96 | |
Operating CF/Net income |
0.01 | (3.30) | 3.54 | (2.31) | |
Capex/Depreciation |
(1.61) | (10.07) | 23.00 | 19.50 | |
Interest Coverage |
(303.02) | (9.23) | (2.88) | (3.60) | |
Research and Development Expense of Revenue |
22.71% | 17.83% | 13.79% | 11.89% | |
Selling, General and Administrative Expense of Revenue |
86.36% | 86.65% | 84.19% | 86.16% | |
Intangible Assets out of Total Assets |
0.03 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
13.99% | 7.64% | 7.38% | 9.44% | |
Graham Net Nets |
0.01 | 0.11 | 0.10 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.32%) | (1.73%) | (1.63%) | (1.98%) | |
Free Cash Flow Yield |
0.64% | 1.72% | (1.35%) | (0.92%) | |
Revenue per Share |
4.19 | 4.01 | 3.77 | 3.63 | |
Operating CF per Share |
(0.13) | 1.41 | (0.57) | 0.46 | |
Capex per Share |
(0.03) | (0.09) | (0.14) | (0.15) | |
Free Cash Flow per Share |
(0.16) | 1.32 | (0.71) | 0.31 | |
Cash per Share |
6.67 | 10.36 | 9.05 | 10.00 | |
Shareholders Equity per Share |
2.24 | 7.99 | 8.12 | 8.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 7.99 | 8.12 | 8.22 | |
Free Cash Flow |
(7.21) | 57.15 | (30.47) | 12.97 | |
Working Capital |
218.30 | 386.24 | 393.72 | 387.09 | |
Capital Expenditures |
(1.21) | (4.07) | (5.82) | (6.36) | |
Net Current Asset Value |
43.95 | 297.58 | 305.05 | 304.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.04 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
88.22 | 79.27 | 90.68 | 67.58 | |
Average Payables |
69.10 | 59.39 | 50.25 | 12.90 | |
Average Inventory |
4.50 | 4.13 | 3.64 | 3.50 | |
Average Assets |
520.03 | 553.07 | 540.94 | 469.57 | |
Average Common Equity |
219.56 | 339.67 | 345.70 | 283.98 |
Columns are period end dates · fundamentals updated 5 Nov 2026